Serologic evaluation in idiopathic interstitial pneumonias

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 5, 2012, Pages 433-440

  Papiris, Spyridon A ^a   Kagouridis, Konstantinos ^a   Bouros, Demosthenes ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

antinuclear autoantibodies; autoimmunity; connective tissue diseases; idiopathic interstitial pneumonias

Indexed keywords

ANTICITRULLINATED PEPTIDE ANTIBODY; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DOUBLE STRANDED DNA; HISTONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RHEUMATOID FACTOR; SIGNAL RECOGNITION PARTICLE; SINGLE STRANDED DNA; SMITH ANTIGEN; UNCLASSIFIED DRUG;

CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; FOLLOW UP; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; MYOSITIS; POLYMYOSITIS; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SEROLOGY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VASCULITIS;

AUTOANTIBODIES; CONNECTIVE TISSUE DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; SEROLOGIC TESTS;

EID: 84864878874     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283560840     Document Type: Review

References (64)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304.
2. Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979; 119:471-503. (Pubitemid 9131394)
3. Tzelepis GE, Toya SP, Moutsopoulos HM. Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J 2008; 31:11-20.
4. Fujita J, Ohtsukib Y, Yoshinouchic T, et al. Idiopathic nonspecific interstitial pneumonia: as an 'autoimmune interstitial pneumonia'. Respir Med 2005; 99:234-240. (Pubitemid 40104280)
5. Sato T, Jiro Fujita J, Yamadori I, et al. Nonspecific interstitial pneumonia as the first clinical presentation of various collagen vascular disorders. Rheumatol Int 2006; 26:551-555.
6. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176:691-697. (Pubitemid 47503077)
7. Park IN, Jegal Y, Kim DS, et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J 2009; 33:68-76.
8. Mittoo S, Gelber AC, Christopher-Stine L, et al. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med 2009; 103:1152-1158.
9. Suda T, Kono M, Nakamura Y, et al. Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD). Respir Med 2010; 104:1527-1534.
10. ij R, North I, Strek ME. Autoimmune-featured interstitial lung disease. A distinct entity. Chest 2011; 140:1292-1299.
11. omagnoli M, Nannini C, Piciucchi S, et al. Idiopathic interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders? Eur Respir J 2011; 38:384-391.
12. orte TJ, Copley SJ, Desai SR, et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012; 39:661-668.
13. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur Respir J 2006; 28:893-896. (Pubitemid 46331953)
14. Tzouvelekis A, Kouliatsis G, Anevlavis S, Bouros D. Serum biomarkers in interstitial lung diseases. Respir Res 2005; 6:78. doi: 10.1186/1465-9921-6-78. (Pubitemid 41410158)
15. Nicholson AG, Colby TV, Wells AU. Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:10-17. (Pubitemid 34298489)
16. Fischer A, West SG, Swigris JJ, et al. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 2010; 138:251-256.
17. Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994; 149:1583-1590. (Pubitemid 24175979)
18. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581-1586. (Pubitemid 34693935)
19. Park JH, Kim DS, Park I, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175:705-711. (Pubitemid 46536486)
20. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44:585-596. (Pubitemid 38845105)
21. avaratnam V, Ali N, Smith CJP, et al. Does the presence of connective tissue disease modify survival in patients with pulmonary fibrosis? Respir Med 2011; 105:1925-1930.
22. deLaurentis A, Veeraraghavan S, Renzoni E. Aspects of ILD: connective tissue disease associated ILD: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 2011; 8:53-82.
23. Cabobianco J, Grimberg A, Thomson BM, et al. Thoracic manifestations of CVD. Radiographics 2012; 32:33-50.
24. Hant FN, Herpel LB, Silver RM. Pulmonary manifestations of scleroderma and mixed connective tissue disease. Clin Chest Med 2010; 31:433-449.
25. Aubart F, Crestani B, Nicaise-Roland P, et al. High levels of anticyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol 2011; 38:979-982.
26. Connors GR, Christopher Stine L, Oddis CV, Danoff SK. ILD associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years. Chest 2010; 138:1464-1474.
27. Papiris SA, Tsonis I, Moutsopoulos HM. Pulmonary complications in Sjögren's syndrome. Semin Respir Crit Care Med 2007; 28:459-472.
28. Alarcon GS. Unclassified or undifferentiated connective tissue disease. Baillieres Best Pract Res Clin Rheumatol 2000; 14:125-137. (Pubitemid 30353028)
29. Carmier D, Marchand-Adam S, Diot P, Diot E. Respiratory involvement in systemic lupus erythematosus. Rev Mal Respir 2010; 27:e66-e78.
30. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009; 33:882-896.
31. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-205. (Pubitemid 18073738)
32. Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569-2581.
33. Medsger TA Jr, Oddis CV. Classification and diagnostic criteria for polymyositis and dermatomyositis. J Rheumatol 1995; 22:581-585.
34. Sharp GC. MCTD and anti-nuclear antibodies. In: Kasukawa R, Sharp GC, editors. Diagnostic criteria for classification of MCTD. Amsterdam: Elsevier; 1987. pp. 23-32.
35. Vitali C, Bombardieri S, Jonsson R, et al. European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554-558. (Pubitemid 34539104)
36. Tan EM, Cohen AS, Fries JF, et al. The1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-1277. (Pubitemid 13221242)
37. Walravens M. Systemic diseases and the detection of nuclear and anticytoplasmic antibodies. A historical review. Clin Rheumatol 1987; 6:9-17. (Pubitemid 17113861)
38. Self S. Autoantibody testing for autoimmune disease. Clin Chest Med 2010; 31:415-422.
39. Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic nonspecific interstitial pneumonia. Report of an American Thoracic Society Project. Am J Respir Crit Care Med 2008; 177:1338-1347. (Pubitemid 351860911)
40. National Heart, Lung, and Blood Institute, NIH. Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful. http://www.nih.gov/ news/health/oct2011/nhlbi-21.htm. [Accessed 3 March 2012]
41. McGrath EE, Millar AB. Hot off the breath: triple therapy for idiopathic pulmonary fibrosis-hear the PANTHER roar. Thorax 2012; 67:97-98.
42. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic pulmonary fibrosis clinical research network investigators: acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176:636-643.
43. Papiris SA, Manali ED, Kolilekas L, et al. IPF exacerbations: unravelling Ariadne's thread. Critical Care 2010; 14:246.
44. Fertig N, Domsic RT, Rodriguez-Reyna T, et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009; 61:958-965.
45. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741-2749. (Pubitemid 37280601)
46. Aggarwal R, Liao K, Nair R, et al. Anticitrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum 2009; 61:1472-1483.
47. Nakashima K, Hagiwara T, Yamada M. Nuclear localization of peptidylarginine deiminase V and histone deamination in granulocytes. J Biol Chem 2002; 277:49562-49568. (Pubitemid 36014395)
48. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127:2019-2027.
49. Dalakas MC. An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2011; 37:226-242.
50. Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 2010; 22:633-638.
51. Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of antimelanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 2012. [Epub ahead of print]
52. Sato S, Hirakata M, Kuwana M, et al. Clinical characteristics of Japanese patients with anti-PL-7 (antithreonyl-tRNA synthetase) autoantibodies. Clin Exp Rheumatol 2005; 23:609-615. (Pubitemid 41300701)
53. Yamasaki Y, Yamada H, Nozaki T, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006; 54:2004-2009. (Pubitemid 43877951)
54. Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL12 autoantibody: cohort study and review of the literature. Chest 2009; 135:1550-1556.
55. Hervier B, Wallaert B, Hachulla E, et al. Clinical manifestations of antisynthetase syndrome positive for antialanyl-tRNAsynthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford) 2010; 49:972-976.
56. La Corte R, Lo Monaco A, Locaputo A, et al. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 2006; 39:249-253. (Pubitemid 43879038)
57. Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren's syndrome. Chest 2006; 130:1489-1495. (Pubitemid 44786744)
58. Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjögren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005; 171:632-638. (Pubitemid 40365420)
59. Papiris SA, Kalomenidis I, Malagari K, et al. Extranodal marginal zone B-cell lymphoma of the lung in Sjögren's syndrome patients: reappraisal of clinical, radiological, and pathology findings. Respir Med 2007; 101:84-92. (Pubitemid 44835236)
60. Mosca M, Tani C, Neri C, et al. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev 2006; 6:1-4. (Pubitemid 44724957)
61. Kallenberg CGM, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006; 12:661-670. (Pubitemid 44830855)
62. Tzelepis GE, Kokosi M, Tzioufas A, et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J 2010; 36:116-121.
63. Arulkumaran N, Periselneris N, Gaskin G, et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford) 2011; 50:2035-2043.
64. Song JW, Do KH, Kim MY, Jang SJ, et al. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009; 136:23-30.